(Reuters) – Pfizer Inc said on Wednesday booster doses of its COVID-19 vaccine produced strong safety and immune responses when co-administered with its pneumonia vaccine in people aged 65 and above in a late-stage study.
The data provides evidence supporting the potential to administer pneumonia shot, PREVNAR 20, and the company’s COVID-19 vaccine at the same time, reducing the number of visits people make to doctors or pharmacies for recommended immunization, Pfizer said.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Vinay Dwivedi)
